Loading
3I
3SBio Inc. Stock: price and insider trades · Hong Kong
1 insider bought €861k of shares over the last 90 days, the latest by Lou Jing, filed 07 Sept 2026.
3SBio Inc.: what insiders have been doing
Every trade that managers of 3SBio Inc. disclose to HKEX is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 24 October 2026, 4 filings were filed, from 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €1.7M, made by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a purchase of €871k by Lou Jing, published on 9 June 2026. Among those who bought: 1 senior executive.
The most recent open-market purchase was published on 7 September 2026, 48 days ago. Filings reach the HKEX feed a median of 1 day after the trade. The shorter that gap, the sooner other investors can see what insiders have done.
For context, the typical company on the same exchange (median of 1,315 companies) published 4 filings over the same period, against 4 filings here. Since 2018, the database holds 13 purchases and 17 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Insider Decl.
42
Thresholds
n/a
Buy Volume
€5M
13 ops. · all time
Sell Volume
€104M
17 ops. · all time
Who traded when
BuySaleLou Jing2 buys1 sale
Zhang Jiaoe3 sales
Since the insiders bought
- -8.8%Entry HK$1.72 · Close at T+30 HK$1.57
- +6.4%Entry HK$9.81 · Close at T+365 HK$10.44
- -13.0%Entry HK$16.20 · Close at T+365 HK$14.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate 3SBio Inc. Strong Buy (bullish), based on 11 analysts. Average price target: HK$29.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 27 of 26,315 companies
94.8
score / 100
Value96
Quality94
FCF yld26%
Earn yld24%
EV/EBITDA3.3x
ROE36%
Gross mgn92%
Net mgn48%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$14.22
Analyst consensus
11 analystsStrong buy
HK$17.03Target HK$29.33(+106%)HK$37.57
Income statement
RevenueHK$17.7B
Gross profitHK$16.3B92% margin
EBITDAHK$11.4B64% margin
Net incomeHK$8.5B46.3% margin
Valuation
PER (trailing)3.8x
PER (forward)12.2x
P/Book1.1x
Beta0.40
Balance sheet & cash
Market capHK$35.2B
Total debtHK$2.6B
Free Cash FlowHK$9.1B
Debt / Equity5%
Profitability & ownership
ROE35.9%
ROA22.7%
% insiders25.0%
% institutions43.3%
Last declaration on 25 September 2026
Declarations42 total
1,500,000 sharesShareXHKGHKEX:DA20260924E00450
490,000 shares@ HK$16.000.013% mcap49.7% of flowShareXHKGHKEX:DA20260907E00254
Canonical exit: 6 Dec 2026 (T+90)
516,000 shares@ HK$15.249750.3% of flowShareXHKGHKEX:DA20260608E00438
Canonical exit: 6 Sept 2026 (T+90)
24,384,630 sharesShareXHKGHKEX:DA20251215E00034
1,500,000 sharesShareXHKGHKEX:DA20250924E00267
440,000 shares@ HK$32.65031.5% of flowShareXHKGHKEX:DA20250730E00440
107,500 shares@ HK$13.3519.0% of flowShareXHKGHKEX:DA20250429E00037
26,000 shares@ HK$12.944.5% of flowShareXHKGHKEX:DA20250416E00347
460,000 shares@ HK$12.4276.5% of flowShareXHKGHKEX:DA20250414E00348
5,000,000 sharesShareXHKGHKEX:DA20240924E00033
Canonical exit: 22 Dec 2024 (T+90)
260,000 shares@ HK$5.78050.2% of flowShareXHKGHKEX:DA20240826E00001
Canonical exit: 21 Nov 2024 (T+90)
982,385 shares@ HK$7.63650.8% of flowShareXHKGHKEX:DA20240424E00238
Canonical exit: 19 Oct 2023 (T+90)
51,553 sharesShareXHKGHKEX:DA20230626E00350
51,553 sharesShareXHKGHKEX:DA20230626E00349
Canonical exit: 14 May 2023 (T+90)
220,000 sharesShareXHKGHKEX:DA20210830E00393
220,000 sharesShareXHKGHKEX:DA20210830E00389
388,500 sharesShareXHKGHKEX:DA20201117E00370
388,500 sharesShareXHKGHKEX:DA20201113E00097
Canonical exit: 28 Dec 2020 (T+90)
1,840,000 shares@ HK$7.99991.6% of flowShareXHKGHKEX:DA20200506E00121
Canonical exit: 28 Jul 2020 (T+90)
599,367,030 sharesShareXHKGHKEX:DA20200331E00427
122,592,477 shares@ HK$7.014596.7% of flowShareXHKGHKEX:DA20200331E00431
134,391,234 sharesShareXHKGHKEX:DA20200323E00301
599,367,030 sharesShareXHKGHKEX:DA20200323E00300
582,832 sharesShareXHKGHKEX:DA20200210E00013
582,832 sharesShareXHKGHKEX:DA20200116E00197
Canonical exit: 26 Mar 2020 (T+90)
25 of 42 declarations
About 3SBio Inc.
3SBio Inc. is a Chinese biopharmaceutical company focused on the research, development, and commercialization of biological products. It primarily targets treatments for kidney diseases and blood disorders.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
